NSE ONESOURCE · BSE 544292 · Biotechnology & Drugs · NIFTY 500
Onesource Specialty Pharma Share Price
Onesource Specialty Pharma Overview
Where the price stands, how it has moved and how it sits against its averages.
Onesource Specialty Pharma shares last traded at ₹1,589.90 on the NSE, down 0.32% on the day. That is 17.4% below the 52-week high of ₹1,924.00 and 47.9% above the 52-week low of ₹1,075.00. Its market value is ₹18,263 Cr.
Price returns
Against the market: 1 Month ▲ +11.43% · 3 Months ▲ +5.04% · 6 Months ▲ +20.40% · This year ▲ +0.43% · 1 Year ▼ −1.68%
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.
Moving averages — price is above 4 of 6
- 100-day average₹1,655.23 ▼ price 3.9% below
- 5-day average₹1,591.72 ▼ price 0.1% below
- Today's price₹1,589.90
- 50-day average₹1,586.92 ▲ price 0.2% above
- 300-day average₹1,583.53 ▲ price 0.4% above
- 10-day average₹1,580.19 ▲ price 0.6% above
- 20-day average₹1,555.43 ▲ price 2.2% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Onesource Specialty Pharma Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹1,422 Cr | ▼ −1.6% | −₹74 Cr | −5.2% | −₹6.44 | — |
| FY 2025 | ₹1,445 Cr | ▲ +740.4% | −₹18 Cr | −1.2% | −₹1.57 | — |
| FY 2024 | ₹172 Cr | ▲ +344.1% | −₹391 Cr | −227.5% | −₹31.96 | ₹0.00 |
| FY 2023 | ₹39 Cr | — | −₹800 Cr | −2,066.2% | −₹36.32 | ₹0.00 |
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹449 Cr | ▲ +4.9% | ₹25 Cr | 5.6% | ₹2.18 |
| Q4 FY26 | ₹428 Cr | ▲ +47.5% | ₹5 Cr | 1.1% | ₹0.40 |
| Q3 FY26 | ₹290 Cr | ▼ −22.7% | −₹89 Cr | −30.6% | −₹7.74 |
| Q2 FY26 | ₹376 Cr | ▲ +14.8% | ₹10 Cr | 2.8% | ₹0.91 |
| Q1 FY26 | ₹327 Cr | ▼ −23.2% | −₹0 Cr | −0.1% | −₹0.02 |
| Q4 FY25 | ₹426 Cr | ▲ +8.5% | ₹99 Cr | 23.1% | ₹8.67 |
| Q3 FY25 | ₹393 Cr | ▲ +17.5% | −₹69 Cr | −17.5% | −₹6.31 |
| Q2 FY25 | ₹334 Cr | — | −₹42 Cr | −12.6% | −₹3.89 |
Balance sheet — FY26
- Total assets₹8,210 Cr
- Total liabilities₹2,379 Cr
- Shareholders' equity₹5,831 Cr
- Total debt₹1,504 Cr
- Cash & investments₹48 Cr
- Current ratio0.99×
- Operating margin (TTM)2.90%
- Net margin (TTM)−3.15%
Cash flow — FY26
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY23–FY26
| ₹ crore | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Total revenue | 38.71 | 171.92 | 1,444.85 | 1,421.59 |
| Cost of revenue | 40.50 | 90.64 | 471.16 | 480.18 |
| Gross profit | −1.78 | 81.28 | 973.70 | 941.41 |
| Operating expenses | 400.34 | 446.01 | 1,361.18 | 1,437.63 |
| Operating income | −361.63 | −274.09 | 83.68 | −16.04 |
| Depreciation | 65.68 | 76.29 | 273.88 | 279.09 |
| Profit before tax | −415.65 | −365.70 | −67.07 | −91.96 |
| Tax | 0.00 | 0.00 | −49.79 | −18.16 |
| Net profit | −799.83 | −391.17 | −17.97 | −73.80 |
| EPS (₹) | −36.32 | −31.96 | −1.57 | −6.44 |
| Dividend per share (₹) | 0.00 | 0.00 | — | — |
| ₹ crore | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Total assets | 2,008.81 | 1,308.61 | 7,550.24 | 8,210.01 |
| Current assets | 228.40 | 176.38 | 1,086.18 | 1,425.94 |
| Cash & short-term investments | 84.33 | 76.12 | 210.53 | 47.52 |
| Inventory | 136.47 | 22.74 | 207.18 | 496.87 |
| Property, plant & equipment | 1,358.09 | 725.17 | 957.73 | 1,239.75 |
| Total liabilities | 1,223.36 | 912.90 | 1,669.66 | 2,378.73 |
| Current liabilities | 865.21 | 630.59 | 1,113.56 | 1,441.97 |
| Total debt | 864.22 | 571.17 | 942.44 | 1,503.94 |
| Total equity | 785.45 | 395.71 | 5,880.58 | 5,831.29 |
| ₹ crore | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| From operations | −162.77 | −107.21 | −67.83 | 8.52 |
| From investing | −67.83 | 510.54 | −201.08 | −494.98 |
| From financing | 118.32 | −390.54 | 412.01 | 359.44 |
| Capital expenditure | −44.00 | −63.77 | −128.15 | −569.07 |
| Dividends paid | — | — | — | — |
| Net change in cash | −112.28 | 12.79 | 143.10 | −127.02 |
What Analysts Say
Recommendations from 4 analysts who cover Onesource Specialty Pharma.
▲ 4 bullish (100.0%) · 0 hold (0.0%) · ▼ 0 bearish (0.0%)
Votes
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | ▲ +1 |
| Buy | 1 | 1 | 1 | 1 | 1 | — |
| Hold | 0 | 0 | 0 | 0 | 0 | — |
| Sell | 0 | 0 | 0 | 0 | 0 | — |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | — |
Analyst ratings are opinions, not a guarantee of returns.
Onesource Specialty Pharma vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Onesource Specialty Pharma | ₹1,589.90 | ▼ −0.32% | ₹18,263 Cr | — | 3.14 | — | −3.15% | 0.00% | This stock |
| Sun Pharmaceutical Industries | ₹1,853.00 | ▼ −0.64% | ₹4,44,586 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% | Moderately Bearish |
| Divi's Laboratories | ₹9,613.00 | ▲ +0.17% | ₹2,55,195 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% | Bullish |
| Torrent Pharmaceuticals | ₹4,935.00 | ▼ −0.90% | ₹1,87,705 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% | Bullish |
| Cipla | ₹1,404.00 | ▲ +1.74% | ₹1,13,423 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% | Neutral |
| Zydus Lifesciences | ₹1,180.00 | ▲ +0.90% | ₹1,17,705 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Onesource Specialty Pharma Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Valuation Is the price reasonable?
Profitability Of every ₹100 of sales, how much is kept?
Returns & efficiency How well does it use its money?
Growth Is the business getting bigger?
Financial strength Can it pay its bills and debts?
Per share What each share stands for
The share price is 3.12× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 74 metrics from the data provider
Valuation
Per share
Margins
Growth
Financial strength
Returns & efficiency
Price & volume
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
- Dividend yield0.00%
No dividends on record.
Corporate calendar
- MeetingAnnual General Meeting
- BoardQuarterly Results
- BoardAudited Results
- BoardQuarterly Results
- BoardQuarterly Results
- MeetingAnnual General Meeting
- BoardQuarterly Results
- MeetingPostal Ballot
Show 3 older events
- MeetingPostal Ballot
- BoardAudited Results
- BoardQuarterly Results
About Onesource Specialty Pharma
Biotechnology & Drugs
OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. It operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The Company specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The Company caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
Key people
- Anurag BhaganiaChief Financial Officer
- Trisha AlladaCompany Secretary, Compliance Officer
- Neeraj SharmaManaging Director, Executive Director
Company facts
- NSE symbolONESOURCE
- BSE code544292
- ISININE013P01021
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹18,263 Cr
- Revenue (FY26)₹1,422 Cr
- Net profit (FY26)−₹74 Cr
In the News
Recent headlines about Onesource Specialty Pharma — they open on Mint in a new tab.
- Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
20 Jul 2026 · 2 min read · Mint ↗ - Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 13 May 2026
The Indian stock market ended Tuesday's session on a lower note. Sumeet Bagadia of Choice Broking recommends five breakout stocks to buy today.
13 May 2026 · 6 min read · Mint ↗ - Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 9 January 2026
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — INOX India, Ramco Cements Limited, Netweb Technologies India, Sobha, and Onesource Specialty Pharma.
9 Jan 2026 · 5 min read · Mint ↗ - Weight-loss drug boom helps OneSource lift revenue target to $500 mn
OneSource Specialty Pharma has raised its FY28 revenue forecast from $400 million to over $500 million, driven by strong demand in its drug-device and biologics sectors.
13 Nov 2025 · 3 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →